Asghar Kashif, Loya Asif, Rana Iftikhar Ali, Bakar Muhammad Abu, Farooq Asim, Tahseen Muhammad, Ishaq Muhammad, Masood Iqra, Rashid Muhammad Usman
Department of Basic Science Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punjab 54000, Pakistan.
Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punjab 54000, Pakistan.
World J Clin Oncol. 2020 Dec 24;11(12):1018-1028. doi: 10.5306/wjco.v11.i12.1018.
Forkhead box P3 (FOXP3) is a specific marker for immunosuppressive regulatory T (T-reg) cells. T-regs and an immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO), are associated with advanced disease in cancer.
To evaluate the co-expression of FOXP3 and IDO in triple negative breast cancer (TNBC) with respect to hormone-positive breast cancer patients from Pakistan.
Immunohistochemistry was performed to analyze the expression of FOXP3, IDO, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor on tissues of breast cancer patients ( = 100): Hormone-positive breast cancer ( = 51) and TNBC ( = 49). A total of 100 patients were characterized as FOXP3 negative positive and further categorized based on low, medium, and high IDO expression score. Univariate and multivariate logistic regression models were used.
Out of 100 breast tumors, 25% expressed FOXP3 positive T-regs. A significant co-expression of FOXP3 and IDO was observed among patients with TNBC ( = 0.01) compared to those with hormone-positive breast cancer. Two variables were identified as significant independent risk factors for FOXP3 positive: IDO expression high (adjusted odds ratio (AOR) 5.90; 95% confidence interval (CI): 1.22-28.64; = 0.03) and TNBC (AOR 2.80; 95%CI: 0.96-7.95; = 0.05).
Our data showed that FOXP3 positive cells might be associated with high expression of IDO in TNBC patients. FOXP3 and IDO co-expression may also suggest its involvement in disease, and evaluation of FOXP3 and IDO expression in TNBC patients may offer a new therapeutic option.
叉头框蛋白P3（FOXP3）是免疫抑制性调节性T（Treg）细胞的特异性标志物。Treg细胞和一种免疫抑制酶，吲哚胺2,3-双加氧酶（IDO），与癌症的晚期疾病相关。
评估巴基斯坦激素阳性乳腺癌患者中三阴性乳腺癌（TNBC）中FOXP3和IDO的共表达情况。
采用免疫组织化学方法分析100例乳腺癌患者（激素阳性乳腺癌51例，TNBC 49例）组织中FOXP3、IDO、雌激素受体、孕激素受体和人表皮生长因子受体的表达。100例患者被分为FOXP3阴性和阳性，并根据IDO表达评分的低、中、高进一步分类。使用单因素和多因素逻辑回归模型。
在100例乳腺肿瘤中，25%表达FOXP3阳性Treg细胞。与激素阳性乳腺癌患者相比，TNBC患者中观察到FOXP3和IDO的显著共表达（P = 0.01）。确定了两个变量为FOXP3阳性的显著独立危险因素：IDO高表达（调整优势比（AOR）5.90；95%置信区间（CI）：1.22 - 28.64；P = 0.03）和TNBC（AOR 2.80；95%CI：0.96 - 7.95；P = 0.05）。
我们的数据表明，TNBC患者中FOXP3阳性细胞可能与IDO的高表达相关。FOXP3和IDO的共表达也可能提示其参与疾病过程，评估TNBC患者中FOXP3和IDO的表达可能提供一种新的治疗选择。
